Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Qualicaps is the third largest producer of hard capsules for oral dosage solutions
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Subscribe To Our Newsletter & Stay Updated
